Humane CD80 Recombinant Fc fusie-eiwit (actief)

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. Cancer Immunotherapy Co- inhibitory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Detection Human extracellular domain CD80 (B7-1) Fc fusion protein. This protein is expressed in CHO-K1 cells and purified using protein G colomn. Protein MW 53 kDa but SDS it runs arround 65 kDa due to glycosylation.

T-lymphocyte activation antigen CD80, Activation B7-1 antigen, BB1, CTLA-4 counter-receptor B7.1, B7, CD28LG, CD28LG1, LAB7

Functional Assay, ELISA, FACS, WB

95% Purity SDS-PAGE and HPLC

Lyophilized from sterile PBS, 5% trehalose and 0.01% tween 80 are added as protectant before lyophilization. Reconstitutes sterile water.

Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Measured by its binding ability in a functional FLOW assay. Binding assay was tested using CHO-K1/CTLA4 cell line (cat no. 14-506ACL) . Endotoxin: <1.0EU per ug of the protein as determin by the LAL method.

Human CD80 (ECD) : MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKE VATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYK NRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLA EVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWL ENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKY GHLRVNQTFNWNTTKQEHFPDN